Legal Cannabis Companies Set to Explode

The legal cannabis movement has seen milestones achieved in the past. In 1996, California became the first state to allow the use of medicinal cannabis for compassionate-use patients and in 2013 Uruguay became the first country worldwide to legalize recreational marijuana. However, in 2018 nothing quite compared to Canada becoming the first industrialized country in the world to legalize cannabis for recreational use. Canadian legalization is opening the door to an estimated $5 billion in annual sales. 

An undiscovered CBD firm CIIX (, Inc.) out of Los Angeles, CA. has started to garner heavy attention from the street.  Start doing your own research on CIIX immediately before the investing public at large discovers it.   CIIX has an interesting CBD business, through its wholly owned subsidiary ChineseHempOil, Inc. and its websites and for online retail, and direct sales of hemp based CBD products.  CIIX is planning a major revenue expansion domestically for its CBD/Hemp based business.  Make sure CIIX is on your radar.  

The projected $5 billion will come in addition to the revenue that growers, processors, distributors, and retailers, are already bringing in from domestic medical marijuana sales and exports to foreign countries where medicinal cannabis is legal. In the near future investors are going to stop looking at marijuana stocks with blinders on and start looking for genuine fundamental progress. That makes brand-building companies an exceptionally high-reward, and high-risk, investment at this time.

These Cannabis related companies are set to explode:, Inc. (OTCQB: CIIX), Canopy Growth Corporation (NYSE: CGC), Cronos Group Inc. (NASDAQ: CRON), Kush Bottles, Inc. (OTCQB: KSHB), GW Pharmaceuticals Plc. (NASDAQ: GWPH)., Inc. (OTCQB: CIIX)

Market Cap: $12.61M, current share price: $0.45, Inc. is currently working with Medicine Man Denver on the creation of a new intellectual property and industry experience based corporate entity that will provide licensing and consulting services within the emerging Cannabis sector. Their subscriber base (free and pay member) is primarily located in the US and Canada.

Canopy Growth Corporation (NYSE: CGC)

Market Cap: $5.72B, current share price: $26.09

Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, Bedrocan Canada, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. 

Cronos Group Inc. (NASDAQ: CRON)

Market Cap: $1.26B, current share price: $6.99

Cronos Group Inc., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada’s Marijuana for Medical Purposes Regulations. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights.

Kush Bottles, Inc. (OTCQB: KSHB)

Market Cap: $304M, current share price: $4.56

Kush Bottles, Inc. is a dynamic sales and distribution platform that provides unique products and services for both businesses and consumers in the cannabis industry.

GW Pharmaceuticals Plc. (NASDAQ: GWPH)

Market Cap: $4.26B, current share price: $151.15

GW Pharmaceuticals plc, is a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. Its lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of efractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. 

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.  ACR Communication, LLC has been compensated one thousand dollars cash for this article and three thousand dollars total by Regal Consulting. LLC, for news commentary articles for CIIX.  CIIX and Regal Consulting, LLC were given an opportunity to edit information included in this article.  This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information.  ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article’s distribution.

For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager


Phone: 1-702-720-6310

Country: United States